Chronic pain can be classified as localised, regional or widespread, and its high prevalence in the general population seems to increase with age. The majority of cases present with musculoskeletal pain. The conditions associated with chronic widespread pain (CWP) are highly burdensome as their characteristic symptoms may include multifocal pain, fatigue, insomnia, memory difficulties and a higher rate of concomitant mood disorders. After many years of debate, it is still unclear whether CWP (central sensitisation) is an entirely explainable neurotransmitter-related process or is partially or totally due to individual cognitive experiences and evaluations. The two models (neurochemical and biopsychosocial) also affect our ability to find therapeutic answers.

Chronic widespread pain : from peripheral to central evolution / P. Sarzi-Puttini, F. Atzeni, P.J. Mease. - In: BAILLIERE'S BEST PRACTICE & RESEARCH: CLINICAL RHEUMATOLOGY. - ISSN 1521-6942. - 25:2(2011 Apr), pp. 133-139.

Chronic widespread pain : from peripheral to central evolution

P. Sarzi-Puttini
;
2011

Abstract

Chronic pain can be classified as localised, regional or widespread, and its high prevalence in the general population seems to increase with age. The majority of cases present with musculoskeletal pain. The conditions associated with chronic widespread pain (CWP) are highly burdensome as their characteristic symptoms may include multifocal pain, fatigue, insomnia, memory difficulties and a higher rate of concomitant mood disorders. After many years of debate, it is still unclear whether CWP (central sensitisation) is an entirely explainable neurotransmitter-related process or is partially or totally due to individual cognitive experiences and evaluations. The two models (neurochemical and biopsychosocial) also affect our ability to find therapeutic answers.
Central; Chronic widespread pain; Fibromyalgia; Pain; Sensitisation; Central Nervous System Diseases; Central Nervous System Sensitization; Chronic Pain; Cognition; Fibromyalgia; Humans; Neurotransmitter Agents; Peripheral Nervous System Diseases; Risk Factors; Somatoform Disorders; Syndrome
Settore MED/16 - Reumatologia
apr-2011
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1521694211000350-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 114.31 kB
Formato Adobe PDF
114.31 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/667509
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 50
  • ???jsp.display-item.citation.isi??? 46
social impact